ZWS Stock Analysis: Zurn Elkay Water Solutions | NYSE
Pollution & Treatment Controls | NYSE, USA | Market Cap: 8.129m USD | 12M Return: 5.7% | US98983L1089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.3M
EPS Trend: 98.5%
Qual. Beats: 11
Rev. Trend: 96.2%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zurn Elkay Water Solutions Corporation designs, manufactures, and markets a broad portfolio of water management products serving institutional, commercial, waterworks, and residential end markets across the U.S., Canada, and internationally. Its offering spans water dispensing and filtration (Elkay, Halsey Taylor), water safety and control valves (Zurn, Wilkins), drainage and flow systems (Zurn, Green Turtle, Wade), sensor-operated flush valves and commercial faucets (Aquaflush, AquaSense, AquaVantage, AquaSpec, Hydro X Power), as well as sinks, restroom partitions, lockers, and hand dryers. The company reaches customers through independent sales representatives, plumbing wholesalers, and industry-specific distributors.
Headquartered in Milwaukee, Wisconsin, Zurn Elkay was founded in 1900 and was renamed from Zurn Water Solutions Corporation in July 2022. Within the broader Industrials sector, ZWS sits in the Building Products sub-industry, a category that includes manufacturers of components used in construction, plumbing, and water infrastructure - markets closely tied to non-residential construction activity, building retrofits, and regulatory standards governing safe drinking water and water conservation.
- Lead and Copper Rule revisions drive water safety product demand
- Non-residential construction backlog pressures institutional sales growth
- Copper and brass input costs compress gross margins amid pricing lag
| Net Income: 276.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.88 > 1.0 |
| NWC/Revenue: 36.88% < 20% (prev 29.47%; Δ 7.41% < -1%) |
| CFO/TA 0.14 > 3% & CFO 401.4m > Net Income 276.1m |
| Net Debt (236.9m) to EBITDA (353.9m): 0.67 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (169.2m) vs 12m ago -0.50% < -2% |
| Gross Margin: 44.77% > 18% (prev 44.55%; Δ 0.22% > 0.5%) |
| Asset Turnover: 63.94% > 50% (prev 60.81%; Δ 3.14% > 0%) |
| Interest Coverage Ratio: 11.97 > 6 (EBIT TTM 310.0m / Interest Expense TTM 25.9m) |
| A: 0.23 (Total Current Assets 953.1m - Total Current Liabilities 312.2m) / Total Assets 2.78b |
| B: -0.38 (Retained Earnings -1.06b / Total Assets 2.78b) |
| C: 0.11 (EBIT TTM 310.0m / Avg Total Assets 2.72b) |
| D: 1.48 (Book Value of Equity 1.66b / Total Liabilities 1.12b) |
| Altman-Z'' = 2.59 = A |
| DSRI: 1.04 (Receivables 270.9m/242.6m, Revenue 1.74b/1.61b) |
| GMI: 1.00 (GM 44.55% / 44.77%) |
| AQI: 0.92 (AQ_t 0.60 / AQ_t-1 0.65) |
| SGI: 1.08 (Revenue 1.74b / 1.61b) |
| TATA: -0.05 (NI 276.1m - CFO 401.4m) / TA 2.78b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of August 29, 2026, the stock is trading at USD 48.05 with a total of 655,793 shares traded. Over the past week, the price has changed by -1.96%, over one month by -2.34%, over three months by +2.44% and over the past year by +5.67%.
Current recommended Stop Loss: 45.00 (which is 6.3% or 2.6 ATR below the current price).
Zurn Elkay Water Solutions has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold ZWS.
- StrongBuy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 58.1 | 20.9% |
P/E Trailing = 30.2531
P/E Forward = 23.9808
P/S = 4.55
P/B = 4.8806
P/EG = 1.5993
Revenue TTM = 1.74b USD
EBIT TTM = 310.0m USD
EBITDA TTM = 353.9m USD
Long Term Debt = 497.7m USD (from longTermDebt, last quarter)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 601.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.4m
Net Debt = 236.9m USD (calculated: Debt 601.9m - CCE 365.0m)
Enterprise Value = 8.37b USD (8.13b + Debt 601.9m - CCE 365.0m)
Interest Coverage Ratio = 11.97 (Ebit TTM 310.0m / Interest Expense TTM 25.9m)
EV/FCF = 22.30x (Enterprise Value 8.37b / FCF TTM 375.1m)
FCF Yield = 4.48% (FCF TTM 375.1m / Enterprise Value 8.37b)
FCF Margin = 21.58% (FCF TTM 375.1m / Revenue TTM 1.74b)
Net Margin = 15.89% (Net Income TTM 276.1m / Revenue TTM 1.74b)
Gross Margin = 44.77% ((Revenue TTM 1.74b - Cost of Revenue TTM 959.8m) / Revenue TTM)
Gross Margin QoQ = 49.77% (prev 47.53%)
Tobins Q-Ratio = 3.01 (Enterprise Value 8.37b / Total Assets 2.78b)
Interest Expense / Debt = 4.30% (Interest Expense 25.9m / Debt 601.9m)
Taxrate = 24.10% (86.6m / 359.3m)
NOPAT = 235.3m (EBIT 310.0m * (1 - 24.10%))
Current Ratio = 3.05 (Total Current Assets 953.1m / Total Current Liabilities 312.2m)
Debt / Equity = 0.36 (Debt 601.9m / totalStockholderEquity, last quarter 1.66b)
Debt / EBITDA = 0.67 (Net Debt 236.9m / EBITDA 353.9m)
Debt / FCF = 0.63 (Net Debt 236.9m / FCF TTM 375.1m)
Total Stockholder Equity = 1.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.16% (Net Income 276.1m / Total Assets 2.78b)
RoE = 17.09% (Net Income TTM 276.1m / Total Stockholder Equity 1.62b)
RoCE = 14.67% (EBIT 310.0m / Capital Employed (Equity 1.62b + L.T.Debt 497.7m))
RoIC = 9.81% (NOPAT 235.3m / Invested Capital 2.40b)
WACC = 9.02% (E(8.13b)/V(8.73b) * Re(9.45%) + D(601.9m)/V(8.73b) * Rd(4.30%) * (1-Tc(0.24)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.69 | Cagr: -1.65%
[DCF] Terminal Value 75.82% ; FCFF base≈337.7m ; Y1≈387.1m ; Y5≈569.7m
[DCF] Fair Price = 44.78 (EV 7.66b - Net Debt 236.9m = Equity 7.43b / Shares 165.9m; r=9.02% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.51 | EPS CAGR: 25.01% | SUE: 1.90 | # QB: 11
Revenue Correlation: 96.22 | Revenue CAGR: 5.57% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.50 | Chg30d=+4.31% | Revisions=+62% | Analysts=11
EPS current Year (2026-12-31): EPS=1.83 | Chg30d=+4.25% | Revisions=+79% | GrowthEPS=+20.6% | GrowthRev=+9.4%
EPS next Year (2027-12-31): EPS=2.04 | Chg30d=+5.86% | Revisions=+75% | GrowthEPS=+11.3% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +85% (up=29, down=1)